Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Walgreens And CVS Agree To Opioid Settlements, But States Waiting To See Details

Executive Summary

As states weigh their options, the history of past settlements will be a factor. One state signed onto the settlement with the distributors but opted out of the deal with J&J, netting it millions more, and with faster payment, than it would have received under the national settlement.

You may also be interested in...



Teva’s New York Opioid Liability Climbs To $523m With Settlement Deal

Teva is on the hook to pay more than $300m to New York state over the next 18 years, in addition to $210m in damages already agreed under its proposed nationwide settlement deal, after settling claims with the New York Attorney General.

Stricken Endo Eyes $6bn Debt Cut With Bankruptcy Filing And Restructuring

A group of Endo debtholders are looking to buy the firm out of bankruptcy, with an initial $6bn bid for the stricken firm that envisions setting aside more than half-a-billion dollars for opioid-related claims. Meanwhile, Endo has reached an agreement-in-principle to resolve opioid-related claims.

Teva Wins Support For Nationwide Opioid Settlement With Bigger Cash Offer

Teva to pay $4.25bn over 13 years under agreement in principle with 12 state attorneys general, Native American tribes and plaintiffs’ lawyers. Previous settlement offer provided mostly medication. Deal is contingent on governments signing on and Allergan inking settlement.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS147257

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel